Smoking is one of the most important factors associated with the development of lung cancer. However, the signaling pathways and driver genes in smoking-associated lung adenocarcinoma remain unknown. The present study analyzed 433 samples of smoking-associated lung adenocarcinoma and 75 samples of non-smoking lung adenocarcinoma from the Cancer Genome Atlas database. Gene Ontology (GO) analysis was performed using the Database for Annotation, Visualization and Integrated Discovery and the ggplot2 R/Bioconductor package. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed using the R packages RSQLite and org.Hs.eg.db. Multivariate Cox regression analysis was performed to screen factors associated with patient survival. Kaplan-Meier and receiver operating characteristic curves were used to analyze the potential clinical significance of the identified biomarkers as molecular prognostic markers for the five-year overall survival time. A total of 373 differentially expressed genes (DEGs; |log2-fold change|≥2.0 and P<0.01) were identified, of which 71 were downregulated and 302 were upregulated. These DEGs were associated with 28 significant GO functions and 11 significant KEGG pathways (false discovery rate <0.05). Two hundred thirty-eight proteins were associated with the 373 differentially expressed genes, and a protein-protein interaction network was constructed. Multivariate regression analysis revealed that 7 mRNAs, cytochrome P450 family 17 subfamily A member 1, PKHD1 like 1, retinoid isomerohydrolase RPE65, neurotensin receptor 1, fetuin B, insulin-like growth factor binding protein 1 and glucose-6-phosphatase catalytic subunit, significantly distinguished between non-smoking and smoking-associated adenocarcinomas. Kaplan-Meier analysis demonstrated that patients in the 7 mRNAs-high-risk group had a significantly worse prognosis than those of the low-risk group. The data obtained in the current study suggested that these genes may serve as potential novel prognostic biomarkers of smoking-associated lung adenocarcinoma.
Introduction
Lung cancer is one of the most prevalent malignancies worldwide. The incidence of lung cancer was 234,030 cases in 2018 (accounting for 27% of new cancer cases), with 154,050 mortalities in 2018 (accounting for 51% of cancer-associated mortalities) (1) . The five-year net survival rate of patients with lung cancer was typically low (10-20% in most nations) (2, 3) . Smoking is a major risk factor for lung cancer. Studies have revealed that lung cancer morbidity and mortality increases with smoking in a dose-dependent manner (4) (5) (6) . Meanwhile, secondhand smoke exposure results in >41,000 mortalities among non-smoking adults each year (7) .
Although the majority of lung cancer cases were the result of smoking, until 2008 10-30% of lung cancer cases worldwide were not due to tobacco use (8, 9) . The development of lung cancer in people who have never smoked (defined as <100 cigarettes in their lifetime) is becoming a growing health problem. Tumors from patients who had never smoked have significant gender, geography, histopathological, molecular and clinical differences when compared with smoking-induced lung cancer tumors (10) . However, the genome-wide similarities and differences between smoking-associated and non-smoking lung adenocarcinoma are largely unknown. Lung adenocarcinoma has surpassed squamous cell carcinoma as the most common histologic subtype in various nations (11, 12) . Therefore, a deeper understanding of the biological characteristics and differences between smoking and non-smoking lung adenocarcinoma may improve the treatment and screening options for patients.
In recent years, several mRNAs, long non-coding RNAs and microRNAs have been identified as biomarkers for the non-invasive detection of various types of cancer, including lung, breast, ovarian, prostate and endometrial cancer (13) (14) (15) (16) (17) non-smoking lung adenocarcinoma in The Cancer Genome Atlas (TCGA) database to identify differentially expressed genes (DEGs) and associated signaling pathways. Multivariate regression analysis showed that seven mRNAs, cytochrome P450 family 17 subfamily A member 1 (CYP17A1), PKHD1 like 1 (PKHD1L1), retinoid isomerohydrolase RPE65 (RPE65), neurotensin receptor 1 (NTSR1), fetuin B (FETUB), insulin-like growth factor binding protein 1 (IGFBP1) and glucose-6-phosphatase catalytic subunit (G6PC), significantly distinguished between non-smoking and smoking adenocarcinomas. These genes may serve as potential non-invasive biomarkers for the diagnosis of smoking-associated lung adenocarcinoma.
Materials and methods
Lung adenocarcinoma patient datasets. The mRNA expression information and corresponding clinical information of patients with lung adenocarcinoma was obtained from The Cancer Genome Atlas (TCGA; tcga-data.nci.nih.gov/tcga). The chosen cohort contained 522 lung adenocarcinoma sample tissues, comprising 433 samples of smoking-associated lung adenocarcinoma, 75 samples of non-smoking lung adenocarcinoma and 14 samples where smoking information was not available generated by the TCGA Research Network (https://www.cancer.gov/tcga). A sample was considered as non-smoking adenocarcinoma if the patient had never smoked or smoked <100 cigarettes in their lifetime (18) . Samples from past and current smokers were pooled together as smoking-associated adenocarcinoma (19, 20) .
Identification of DEGs between smoking and non-smoking lung adenocarcinoma. Differential mRNA expression between smoking and non-smoking lung adenocarcinoma was evaluated using the edgeR package in R/Bio conductor (version 3.26.5; http://www.bioconductor.org/packages/release/bioc/html/edgeR.html) (21) . The DEGs between the data sets were obtained using |log2-fold change|≥2.0 and P<0.01 as cut-off criteria. curves were used to analyze the potential clinical significance of these biomarkers as molecular prognostic markers for the five-year overall survival. Kaplan-Meier curves were constructed using the R package survival (CRAN.R-project.org/package=survival. ROC curves were constructed using the R package survival ROC (version 1.0.3; CRAN.R-project.org/package=survivalROC). The risk heat map was constructed using the R package pheatmap (version 1.0.12; CRAN.R-project.org/package=pheatmap) and had a significant impact on survival.
Results
Differentially expressed mRNAs in smoking-associated lung adenocarcinoma compared with non-smoking lung adenocarcinoma. Analysis of TCGA transcription data from 433 smoking-associated lung adenocarcinoma samples and 75 non-smoking lung adenocarcinoma samples revealed that 373 mRNAs were differentially expressed (|log2-fold change|≥2.0 and P<0.01). Of these DEGs, 71 mRNAs were downregulated while 302 mRNAs were upregulated. These results demonstrated that the gene profiles of smoking and non-smoking lung adenocarcinomas were significantly different. The DEGs are displayed in a heat map and a volcano map ( Fig. 1A and B). Detailed differential mRNA expression levels are presented in Table I .
GO functional predictions of DEGs in smoking-associated adenocarcinoma.
To predict the function of aberrantly expressed genes, GO functional data were downloaded from DAVID. Differential mRNA expression analysis was performed with three functional assemblies: Biological process, cellular component and molecular function ( Fig. 2A and B) . A total of 28 significant GO functions with an FDR<0.05 were identified. The top 10 GO functions and corresponding genes are presented in Fig. 2C . Detailed GO results are presented in Table II . The present study demonstrated that 'nucleosomes' was the most significant GO term for the identified DEGs.
KEGG pathway enrichment of differentially expressed mRNAs.
To predict the KEGG pathway enrichment for the identified DEGs, pathway enrichment data were downloaded from KEGG. A total of 11 significantly KEGG pathways with an FDR<0.05 were identified and R software was used to analyze downloaded data. The KEGG pathways analyzed included: 'Systemic lupus erythematosus', 'alcoholism', 'steroid hormone biosynthesis', 'viral carcinogenesis', 'cortisol synthesis and secretion', 'taste transduction', 'maturity-onset diabetes of the young', 'ovarian steroidogenesis', 'cholesterol metabolism', 'aldosterone synthesis and secretion' and 'peroxisome proliferator-activated receptor signaling pathway' (Fig. 2D and Table III ). The majority of the DEGs were significantly enriched in the 'systemic lupus erythematosus' pathway. Notably, genes associated with histones, which are an important part of nucleosomes, were identified in this pathway.
Construction of a PPI network using the DEGs. PPI network analysis was performed using the STRING online database and Cytoscape software. A total of 238 proteins were analyzed ( Fig. 3 ) and the tightly linked hub genes in the PPI network were calculated using MCODE. The top 5 most significant gene clusters were identified (Table IV) . These genes may serve an important role in the development of smoking-associated lung adenocarcinoma.
Cox proportional hazards regression model. T he R/Bioconductor packages survival, survivalROC and pheatmap were used to calculate the prognostic survival of patients in the smoking-associated lung adenocarcinoma group. Seven mRNAs were significantly associated with overall survival, including CYP17A1, PKHD1L1, RPE65, NTSR1, FETUB, IGFBP1, and G6PC. Using the median of the prognostic risk score (0.94) as a cut-off point, these 7 mRNAs were assigned to each patient in the high-risk (n=207) or low-risk (n=207) smoking-associated lung adenocarcinoma groups. The Kaplan-Meier estimate was used to calculate the high-risk and low-risk patient cohort overall survival for the 7 mRNA signatures in patients. Patients in the high-risk group had a significantly worse prognosis compared with the low-risk group (P<0.001; Fig. 4A ). ROC analysis was used to assess the sensitivity and specificity of the 7 mRNA markers for the prediction of the five-year Table I . Differentially expressed genes in smoking-associated lung adenocarcinoma compared with non-smoking adenocarcinoma.
A , Upregulated genes   CALB1, HIST1H4C, HIST1H1E, HIST1H1B, POU5F2, HIST1H4B, HIST2H2AB, HIST1H4E, HIST1H2BB, WFDC5,  HIST1H4D, HIST1H1D, HIST1H2BI, PNMA5, HIST1H3B, HIST1H2AB, WFDC12, HIST1H2AJ, TEX19, KIR2DL1,  HIST1H2BL, MSTN, HIST1H2AH, HIST1H2BE, GPR22, HIST1H3C, TAS2R30, NNAT, NTS, APOA1, GPR52, DHRS2,  HIST1H2BM, HIST2H2AC, HIST1H3F, PRH2, HIST1H4A, HIST1H2BH, HIST1H3J, LRRC38, APOA2, AFP, HIST1H1A,  HIST1H3A, HIST1H2AL, HIST1H3I, PRB4, HIST1H2BO, HIST2H3D, NECAB2, PRB3, CHGA, HRG, INSM1, TAC3,  IFNK, MYT1, MAEL, SCG2, HIST1H4F, PRSS48, ACTN3, HIST1H4L, C10orf113, NSG2, HIST1H2BF, VTN, IRX4, SPIC,  LRRTM2, TAS2R13, GAL, DPPA2, PSG11, FABP7, TKTL1, SEZ6, ZPBP2, NKX2-3, PSG1, KCNH6, ADGRB1, GABRA2,  TAS2R46, TUBA3E, ADAM20, PSG8, STXBP5L,4-Mar, OR6T1, ANGPTL3, ZP2, PSG5, F2, TAGLN3, PSG3, HBE1, FXYD4,  SERPINB13, TDRD12, PNMA6E, SPATA21, CDK5R2, BOLL, RPE65, SPINK4, HIST1H2AD, PTPRN, HMX2, SPRR2E (Fig. 4B) . Therefore, the model exhibits a high predictive power that could be used to predict the overall survival of patients with smoking-associated lung adenocarcinoma. To better understand the association between the expression of these 7 mRNAs and the survival time of patients, a risk heat map of these mRNAs in combination with clinical survival data was generated (Fig. 4C) .
Discussion
Lung cancer is the main cause of oncogenic mortality in males and females worldwide. In spite of improved understanding of oncogenic drivers, few studies have identified genes that are differentially expressed between smoking and non-smoking lung adenocarcinoma. The elucidation of the mechanisms underlying the pathogenesis of smoking-associated lung adenocarcinoma is a challenging task. The current study used bioinformatics methods to analyze 433 samples of smoking-associated lung adenocarcinoma and 75 samples of non-smoking lung adenocarcinoma. A total 373 mRNAs that were differentially expressed between the two groups were identified. Of these, 71 mRNAs were downregulated and 302 mRNAs were upregulated. To predict the function of aberrantly expressed genes, pathway analysis was performed and 28 significant GO functions and 11 significantly enriched KEGG pathways were identified. The Cox proportional hazards regression model suggested that 7 mRNAs may be used as prognostic indicators: CYP17A1, PKHD1L1, RPE65, NTSR1, FETUB, IGFBP1 and G6PC. The AUC of the 7 mRNAs analyzed was 0.769 (95% CI, 0.70-0.83), which indicated that the model had a good predictive value (25) . CYP17A1 is a qualitative regulator of human steroid biosynthesis (26) . It is a potential non-small cell lung cancer (NSCLC) susceptibility candidate gene, which converts testosterone to estradiol in hormone-associated cancers (27) . Olivo-Marston et al (28) revealed a small yet significant association between the CYP17A1 rs743572 polymorphism and lower serum estrogen and improved survival of patients with NSCLC. While Zhang et al (29) demonstrated that CYP17A1 polymorphisms were not associated with NSCLC development in Asian patients. PKHD1L1 has been implicated in lymph node metastasis in endometrial cancer (30) . Mutation of PKHD1L1 served an important role in patients with early high-grade serous ovarian cancer (31) . RPE65 is highly expressed in the retinal pigment epithelium and encodes an isomerohydrolase that is required for converting all-trans-retinyl esters into 11-cis-retinal, the natural ligand and chromophore for the opsins in rod and cone photoreceptor cells (32) . NTSR1 and its ligand neurotensin are frequently overexpressed in tumors of epithelial origins. This ligand/receptor complex contributes to the progression of several tumor types, such as liver cancer or prostate cancer, via the activation of the biological processes involved in tumor progression (33, 34) . The monoclonal antibody against NTSR1 restores sensitivity to platinum-based therapy and decreases metastasis in lung cancer (35) . FETUB, a liver-derived plasma protein, has recently been reported to influence glucose metabolism (36) . FETUB copy number amplification in human esophageal cancer, head and neck squamous cell carcinoma was at least 10-23% (37) . FETUB was associated with decreased lung function in patients with chronic obstructive pulmonary disease (COPD), and predicted the occurrence of acute exacerbation or frequent acute exacerbation (38) . FETUB, in combination with other markers, may have diagnostic and prognostic value in COPD.
IGFBP1-6 are high-affinity regulators of insulin-like growth factor (IGF) activity and modulate important biological processes, including cell proliferation, survival, migration, senescence, autophagy, angiogenesis, differentiation and apoptosis (39, 40) . Apart from inhibiting the actions of IGF by inhibiting binding to the IGF-1 receptor, IGFBP1 also performs IGF-independent actions, including the modulation of other growth factors, nuclear localization, transcriptional regulation and binding to non-IGF molecules involved in tumorigenesis, growth, progression and metastasis (41) . The expression and function of IGFBP1 in stimulating or inhibiting lung cancer growth have yet to be elucidated (39) . G6PC catabolizes glucose-6-phosphate (G6P) to glucose and inorganic phosphate, thereby preventing the accumulation 1  30  420  HIST1H4C, HIST1H3F, HIST1H4D, HIST1H4L, HIST1H4E, HIST1H3A,  HIST1H4F, HIST1H3I, HIST1H2AH, HIST1H4B, HIST2H2AC, HIST2H2AB,  HIST1H2BH, HIST1H2AB, HIST1H2AJ, HIST2H3D, HIST1H2BM, HIST1H4A,  HIST1H2BL, HIST1H2BA, HIST1H2BF, HIST1H2BB, HIST1H2BO,  HIST1H2AD, HIST1H3J, HIST1H3B, HIST1H3C, HIST1H2BE, HIST1H2AL,  HIST1H2BI  2  16  89  NPY, GAL, TAS2R13, ALB, KNG1, GCG, TAS2R46, GNAT3, HRH3, TAS2R43,  TAS2R3, TAC1, CASR, TAS2R30, NTS, TAS2R50  3  23 of G6P, which regulates oxidative metabolism of cancer cells (42) . While primarily thought of as an hepatic enzyme that serves a major role in glucose homeostasis, G6PC is dysregulated in an array of human tumor types, such as ovarian cancer (43) . Lack of G6PC expression decreased liver cell immunity and promoted tumor development in patients with glycogen storage disease (44, 45) .
In conclusion, the present study evaluated the mRNA expression of 433 patients with smoking-associated lung adenocarcinoma and 75 patients with non-smoking lung adenocarcinoma. A total of seven genes were identified to have high diagnostic sensitivity and specificity associated with overall survival of patients with smoking-associated lung adenocarcinoma patients. The lack of experimental data to verify these findings is a limitation of the present study. It will be interesting to further explore the roles of CYP17A1, NTSR1, FETUB, IGFBP1 and G6PC in the development of smoking-associated lung adenocarcinoma. (B) ROC curves of the sensitivity and specificity of 7 mRNAs in overall survival prediction in patients. (C) A risk heat map constructed from 7 mRNAs that had a significant impact on survival from 414 patients. The risk value gradually increases from left to right. ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval; CYP17A1, cytochrome P450 family 17 subfamily A member 1; FETUB, fetuin B; G6PC, glucose-6-phosphatase catalytic subunit; IGFBP1, insulin-like growth factor binding protein 1; NTSR1, neurotensin receptor 1; PKHD1L1, PKHD1 like 1; RPE65, retinoid isomerohydrolase RPE65.
